# US 6,730,669 B2 · Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,669 B2
- Document ID: US6730669B2
- Status: Granted
- Kind: B2
- Application number: 10/200,589
- Filed: 2002-07-23
- Published: 2003-11-20
- Granted: 2004-05-04
- Earliest claimed: 1995-03-10
- Assignees: G. D. Searle & Co.
- Inventors: Daniel P Getman; Gary A. DeCrescenzo; John N. Freskos; Michael L. Vazquez; James A. Sikorski; Balekudru Devadas; Srinivasan Nagarajan; David L. Brown; Joseph J. McDonald
- Web page: https://patentgrep.com/patent/US6730669B2

## CPC

- C07D 307/79: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 235/30: Nitrogen atoms not forming part of a nitro radical
- C07D 277/62: Benzothiazoles
- C07D 295/15: to an acyclic saturated chain
- C07D 311/58: other than with oxygen or sulphur atoms in position 2 or 4
- C07D 317/62: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D 319/18: Ethylenedioxybenzenes, not substituted on the hetero ring
- C07D 339/06: having the hetero atoms in positions 1 and 3, e.g. cyclic dithiocarbonates
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07K 5/06026: {the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala}
- C07K 5/06034: {the side chain containing 2 to 4 carbon atoms}
- C07K 5/0606: {the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr}
- C07K 5/06069: {Ser-amino acid}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Selected amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.

## Claims

### Claim 1

Compound represented by the formula:
or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein n represents 1 or 2;
R1 represents an alkyl of 1-5 carbon atoms, an alkenyl of 2-5 carbon atoms, an alkynyl of 2-5 carbon atoms, a hydroxyalkyl of 1-3 carbon atoms, an alkoxyalkyl of 1-3 alkyl and 1-3 alkoxy carbon atoms, a cyanoalkyl of 1-3 alkyl carbon atoms, imidazolylmethyl —CH2CONH2, —CH2CH2CONH2, —CH2S(O)2NH2, —CH2SCH3, —CH2S(O)CH3, —CH2S(O)2CH3, —C(CH3)2SCH3, —C(CH3)ZS(O)CH3or —C(C113)S(O)zCH3radicals;
R2 represents an alkyl of 1-5 carbon atoms, an aralkyl of 1-3 alkyl carbon atoms, an alkylthioalkyl of 1-3 alkyl carbon atoms, an arylthioalkyl of 1-3 alkyl carbon atoms, or a cycloalkylalkyl of 1-3 alkyl carbon atoms and 3-6 ring member carbon atoms;
R3 represents an alkyl of 1-5 carbon atoms, a cycloalkyl of 5-8 ring members or a cycloalkylmethyl radical of 3-6 ring members;
A and B each independently represent CH2, O, S, SO or SO2;
R6 represents hydrogen, deuterium, an alkyl of 1-5 carbon atoms, fluoro or chloro,
R7 represents hydrogen, deuterium, methyl, fluoro or chloro;
R7 represents hydrogen; alkyl hydroxyalkyl or alkoxyalkyl radicals, wherein alkyl is 1-3 carbon atoms;
R11 represents hydrogen, alkyl of 1-5 carbon atoms, hydroxyalkyl of 1-4 carbon atoms, alkoxyalkyl of 1-3 alkyl carbon atoms, benzyl, imidazolylmethyl, —CH2CH2CONH2, —CH2CONH2, —CH2CH2SCH3, or —CH2SCH3radicals or the sulfone or sulfoxide derivatives thereof;
R12 represents hydrogen, hydroxyalkyl or alkoxyalkyl radicals, wherein alkyl is 1-3 carbon atoms; and
R13 and R14 each independently represent hydrogen, hydroxy, alkoxy, 2-hydroxyethoxy, hydroxyalkyl or alkoxyalkyl radicals, wherein alkyl is 1-3 carbon atoms; or R12 and R13 or and R14 along with the carbon atoms to which they are attached represent 5-6 ring membered heteroaryl or benzo radical, each of which is optionally substituted with at least one hydroxy or alkoxy radical of 1-3 carbon atoms.

### Claim 2 (depends on 1)

Compound of claim 1, or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein
R1 represents alkyl of 1-4 carbon atoms, alkenyl of 2-3 carbon atoms, alkynyl of 3-4 carbon atoms, cyanomethyl, imidazolylmethyl, —CH2CONH2, —CH2CH2CQNH2, —CH2S(O)2NH2, —CH2SCH3, —CH2S(O)CH3, —CH2S(O)2CH3, —C(CH3)2SCH3, —C(CH3)2S(O)CH3or —C(CH3)2S(O)2CH3radicals;
R2 represents radicals of alkyl of 3-5 carbon atoms, arylmethyl, alkylthioalkyl of 1-3 alkyl carbon atoms, arylthiomethyl or cycloalkylmethyl of 5-6 ring member carbon atoms radicals;
R3 represents alkyl of 1-5 carbon atoms, cycloalkylmethyl of 3-6 ring members, cyclohexyl or cycloheptyl radicals.

### Claim 3 (depends on 2)

Compound of claim 2, or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein
R1 represents iso-propyl, sec-butyl, tert-butyl, 3-propynyl, imidazolylmethyl —CH2CONH2, —CH2SCH3, —CH2S(O)CH3, —CH2S(O)2CH3, —C(CH3)2SCH3, —C(CH3)2S(O)CH, or —C(CH3)2S(O)2CH3radicals;
R2 represents isobutyl, n-butyl, CH3SCH2CH2—, phenylthiomethyl, (2-naphthylthio)methyl, benzyl, 4-methoxyphenylmethyl, 4-hydroxyphenylmethyl, 4-fluorophenylmethyl or cyclohexylmethyl radicals;
R3 represents propyl, isoamyl, isobutyl, butyl, cyclohexyl, cycloheptyl, cyclopentylmethyl or cyclohexylmethyl radicals;
R10 and R12 each represent a hydrogen radical;
R11 represents hydrogen, methyl, isopropyl, butyl, secbutyl, isobutyl, hydroxymethyl or hydroxyethyl radicals; and
R13 and R14 each independently represent hydrogen, hydroxy, methoxy or ethoxy radicals; or R12 and R13 or R13 and R14 along with the carbon atoms to which they are attached represent benzo radical, which is optionally substituted with at least one hydroxy or methoxy radical.

### Claim 4 (depends on 1)

Compound of claim 1 or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein n represents 1;
R1 represents sec-butyl, tert-butyl, iso-propyl, 3-propynyl or —C(CH3)2S(O)2CH3radicals;
R2 represents benzyl, 4-fluorophenylmethyl or cyclohexylmethyl radicals;
R11 represents a hydrogen radical; and
R13 and R14 each independently represent hydrogen, hydroxy, methoxy or ethoxy radicals.

### Claim 5 (depends on 1)

Compound of claim 1 wherein said pharmaceutically acceptable salt is hydrochloric acid salt, sulphuric acid salt, phosphoric acid salt, oxalic acid salt, maleic acid salt, succinic acid salt, citric acid salt or methanesulfonic acid salt.

### Claim 6 (depends on 5)

Compound of claim 5 wherein said pharmaceutically acceptable salt is hydrochloric acid salt, oxalic acid salt, citric acid salt or methanesulfonic acid salt.

### Claim 7 (depends on 1)

Composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 8 (depends on 1)

Method of inhibiting a retroviral protease comprising administering an effective amount of a compound of claim 1.

### Claim 9 (depends on 7)

Method of treating a retroviral infection comprising administering an effective amount of a composition of claim 7.

### Claim 10 (depends on 1)

Method of inhibiting replication of a retrovirus comprising administering an effective amount of a compound of claim 1.

### Claim 11 (depends on 1)

Method of preventing replication of a retrovirus in vitro comprising administering an effective amount of a compound of claim 1.

### Claim 12 (depends on 7)

Method of treating AIDS comprising administering an effective amount of a composition of claim 7.

### Claim 13 (depends on 1)

Compound of claim 1 wherein the absolute stereochemistry of the carbon atom of the —CH(OH)— group is (R), the absolute stereochemistry of the carbon atom of the —CH(R1)— group is (S) and the absolute stereochemistry of the carbon atom of the —CH(R2)— group is (S).

### Claim 14

Compound of claim wherein the absolute stereochemistry of the carbon atom of the —CH(OH)— group is (R), the absolute stereochemistry of the carbon atom of the —CH(R1)— group is (5) and the absolute stereochemistry of the carbon atom of the —CH(R2)— group is (S).

### Claim 15 (depends on 3)

Compound of claim 3 wherein the absolute stereochemistry of the carbon atom of the —CH(OH)— group is (R), the absolute stereochemistry of the carbon atom of the —CH(R1)— group is (S) and the absolute stereochemistry of the carbon atom of the —CH(R2)— group is (S).

### Claim 16 (depends on 4)

Compound of claim 4 wherein the absolute stereochemistry of the carbon atom of the —CH(OH)— group is (R), the absolute stereochemistry of the carbon atom of the —CH(R1)— group is (S) and the absolute stereochemistry of the carbon atom of the —CH(R2)— group is (S).
